Abstract:Background . Pancreatic cancer (PC) is a deadly disease with poor prognosis in the general population. We aimed to quantitate overall survival of patients with PC after irreversible electroporation (IRE) and the incidence of relevant complications. Methods . We performed a literature search via five electronic databases (PubMed, Embase, Web of Science, Scopus, and Cochrane Library databases) up to August 2017. The primary outcomes were overall survival and prognosis. Secondary outcomes included the response of post-IRE complications. Fixed-effects or random-effects meta-analysis was conducted to pool these data. Results . A total of 15 eligible articles involving 535 patients were included. The primary outcomes showed that the pooled prevalence estimates of overall survival were 94.1% (95% CI: 90.7–97.5), 80.9% (95% CI: 72.5–89.4), 54.5% (95% CI: 38.3–70.6), and 33.8% (95% CI: 14.2–53.5) at 3, 6, 12, and 24 months, and the pooled prevalence data of complete response (CR) at 2 months, partial response (PR) at 3 months, and progression at 3 months were 12.5% (95% CI: 2.9–22.2), 48.5% (95% CI: 39.4–57.6), and 19.7% (95% CI: 7.3–32.2), respectively. The secondary outcomes showed that the pooled prevalence values of post-IRE complications were abscess 6.6% (95% CI: 0.2–13), fistula 10.6% (95% CI: 2.5–18.7), pain 33.5% (95% CI: 14.5–52.5), infection 16.1% (95% CI: 3.9–28.4), thrombosis 4.9% (95% CI: 1.2–8.5), pancreatitis 7.2% (95% CI: 3.1–11.2), bleeding 4.2% (95% CI: −0.5–8.9), cholangitis 4.2% (95% CI: −0.5–8.9), nausea 9.6% (95% CI: 4.4–14.8), biliary obstruction 13.8% (95% CI: 4.2–23.3), chest tightness 7.6% (95% CI: 0.5–14.6), and hypoglycemia 5.9% (95% CI: −0.4–12.2). Conclusions . This meta-analysis indicated a clear survival benefit for PC patients who received irreversible electroporation therapy, although future safety and effectivity monitoring from more large-scale studies will be needed.

Irreversible Electroporation Ablation for the Treatment of Pancreatic Cancer: Present and Prospects

The interventional therapeutics of irreversible electroporation for pancreatic cancer

Irreversible Electroporation: Expanding the Armamentarium against Pancreatic Cancer

Irreversible electroporation for the management of pancreatic cancer: Current data and future directions

Irreversible Electroporation for Locally Advanced Pancreatic Cancer

Irreversible electroporation and the pancreas: What we know and where we are going?

Irreversible electroporation stimulates a pro-inflammatory tumor microenvironment in pancreatic cancer

Physical and Chemical Enhancement of and Adaptive Resistance to Irreversible Electroporation of Pancreatic Cancer

Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers

System Analysis of Clinical Application of Irreversible Electroporation for Pancreatic Cancer

The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy

Irreversible Electroporation: Background, Theory, and Review of Recent Developments in Clinical Oncology

Irreversible electroporation for the ablation of pancreatic malignancies: A patient‐specific methodology

Irreversible electroporation: Beyond the limits of tumor ablation

The effects of irreversible electroporation triggering anti-tumor immunity and the value of its combination with immunotherapy

Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist

Research Progress of Catheter-based Irreversible Electroporation for Tissue Ablation

Past and Present of Irreversible Electroporation for Tumor Ablation

Irreversible Electroporation in Patients with Pancreatic Cancer: How Important Is the New Weapon?

Irreversible Electroporation Therapy in the Management of Locally Advanced Pancreatic Adenocarcinoma

Cancer Treatments of the Irreversible Electroporation